The Master Deployment Agreement can cover multiple funded research projects over 5 years, potentially involving over 1,000 patients.
News in Summary
KITCHENER, ON / ACCESSWIRE / March 6, 2024 / Cloud DX (TSXV:CDX) (OTCQB:CDXFF), a leading North American provider of virtual care and remote patient monitoring platforms is pleased to announce a new Master Deployment Agreement with the Ottawa Hospital Research Institute (OHRI).
OHRI is an academic health research institute located in the city of Ottawa, Ontario. It is the research arm of The Ottawa Hospital and is affiliated with the University of Ottawa.
OHRI houses approximately 2,200 scientists, clinician investigators, students, research fellows, and support staff. Its researchers are studying more than a hundred different diseases, conditions and specialties with an overall focus on translating discoveries and knowledge into better health.
Researchers at the Institute intend to use Cloud DX Connected Health products and services to enable remote patient monitoring, communication via video and text, schedule and compliance management, and improved clinical study efficiencies, allowing the researchers to conduct higher quality clinical studies. Cloud DX technology will make it possible to recruit subjects for trials more efficiently, and to gather more information from each subject. Each order for Cloud DX technology will be covered by a separate Statement of Work (SOW), with plans in place for projects involving over 1,000 patients.
Cloud DX has a successful track record of academic partnership, working with prestigious institutions such as the Population Health Research Institute, McMaster University, University of New Brunswick, University of Waterloo, University of California San Diego, Simon Fraser University and several others. Researchers have published papers describing the benefits of Cloud DX technology in peer reviewed journals including the British Medical Journal, the Canadian Journal of Cardiology and Journal of Medical Internet Research.
Dr Sylvie Aucoin, clinician investigator at the Ottawa Hospital Research Institute and anesthesiologist at The Ottawa Hospital commented: "Virtual care and remote monitoring technologies have great potential to improve patient care. Our research team looks forward to working with CloudDx on research in this area."
Cloud DX Co-founder and COO Anthony Kaul stated: "Cloud DX is excited to embark on this new partnership with the Ottawa Hospital Research Institute. Since our founding in 2014 Cloud DX has participated in some of the most important research in digital health. Papers published about virtual care using Cloud DX, including the PVC-RAM-1 study in the British Medical Journal, have been cited around the world. Our research partnerships often lead to large-scale commercial contracts, as was the case with long-term clients Hamilton Health Sciences, The Ottawa Hospital, Alberta Health Services, and others. We're confident that our contributions to research at OHRI will continue to improve care for Canadians, and customers in other countries as well."
About Cloud DX
Accelerating digital healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. The Company is the co-winner of the Qualcomm Tricorder XPRIZE, winner of "2022 Top Innovator" from Canadian Business, a 2021 "Edison Award" winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." Cloud DX is an exclusive partner to Medtronic Canada, Teladoc Health Canada and Sanrai International.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx
Social Links
Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/
For media inquiries please contact:
Marketing Enquiries
Phone 888-543-0944
This email address is being protected from spambots. You need JavaScript enabled to view it.
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
Phone 647-881-8418
This email address is being protected from spambots. You need JavaScript enabled to view it.
Officer responsible for this Press Release:
Robert Kaul
Chief Executive Officer
Phone 888-543-0944
This email address is being protected from spambots. You need JavaScript enabled to view it.
Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. In particular, this news release includes certain forward-looking statements concerning the terms of the contract extension, the expected proceeds therefrom, as well as management's objectives, strategies, beliefs and intentions.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the Company's the ability of the Company to fulfill the terms of and derive the benefits from the contract extension.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.
À propos de Cloud DX
Accélérant les soins de santé virtuels, Cloud DX a pour mission d'améliorer les soins de santé pour tous. Notre plateforme de surveillance à distance des patients Connected HealthMC est utilisée par des entreprises de soins de santé et des équipes de soins partout en Amérique du Nord pour gérer virtuellement les maladies chroniques, permettre aux gens de vieillir chez eux et fournir des soins post-chirurgicaux de qualité hospitalière à domicile. Nos partenaires obtiennent de meilleurs résultats pour les soins de santé et les patients, réduisent le besoin d'hospitalisation ou de réadmission, et réduisent les coûts de prestation des soins de santé grâce à une utilisation plus efficace des ressources. Cloud DX est co-lauréate du prix Qualcomm Tricorder XPRIZE, lauréate du prix Edison 2021, finaliste du concours « World Changing Idea » de Fast Company et un des dix plus importants fournisseurs de télésanté au Canada.
Site des relations avec les investisseurs de Cloud DX https://ir.clouddx.com/overview/default.aspx
La Bourse de croissance TSX et son fournisseur de services de réglementation (tel que ce terme est défini dans les politiques de la Bourse de croissance TSX) n'assument aucune responsabilité quant à la pertinence ou à l'exactitude du présent communiqué.
Tous les énoncés prospectifs sont assujettis à des risques et à des incertitudes, tels que ceux décrits dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission. Les résultats réels peuvent sensiblement différer des résultats anticipés.
Last Trade: | C$0.13 |
Daily Volume: | 0 |
Market Cap: | C$11.640M |
April 29, 2024 April 23, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB